Report from the Medical Products Agency's Consumer and Patient Council

The Swedish Medical Products Agency's Consumer and Patient Council met on October 12. During the day, the updates on the Covid-19 vaccine were discussed. The latest booster vaccine has a different approval process as the Covid-19 vaccine has been tested more extensively than any previous vaccine.

Smallpox vaccine is available, but there has been a shortage of suppliers in the initial emergency phase.

Residual listings of medicines have increased in Sweden, the Swedish Medical Products Agency reports today. They announce that when the Medical Products Agency will take over the presidency of the EU in 2023, the supply issue will be prioritized. In Sweden, there is no authority that is responsible but only supervision, which means that there is a shortage in the entire supply chain. Stockpiling must be done both from the defense and the regions, which have received extra funds for this. They emphasized the importance of encouraging our members to pick out an extra can, that is, take out when you have a can left at home.

Pharmaceutical companies are required to report two months in advance. When this happens, a forecast can be viewed on the MPA website, or FASS.

Simon Blom, Ombudsman